On the other hand, pralsetinib was assess in the open-label phase I/II ARROW study, in which 114 RET+ advanced NSCLC patients (87 pretreated and 27 naïve ones) received pralsetinib in monotherapy. Here, RET is linked to non-small cell lung carcinoma.